2023-09-13 | Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding PDF Report Presentation Webcast
Regulatory 2023-08-31 | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results PDF Report Presentation Webcast
Regulatory 2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE PDF Report Presentation Webcast
2023-08-09 | Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 PDF Report Presentation Webcast
2023-04-25 | Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences PDF Report Presentation Webcast
Regulatory 2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-03 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
2023-03-14 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards Launch PDF PDF Report Presentation Webcast
Regulatory 2023-03-13 | Ascelia Pharma Mourns the Passing of Board Member René Spogárd PDF Report Presentation Webcast
2023-03-13 | Third US patent strengthens patent protection for Ascelia Pharma’s Oncoral (daily tablet irinotecan) PDF Report Presentation Webcast
2023-03-06 | INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH PDF Report Presentation Webcast
2023-03-03 | Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients. PDF Report Presentation Webcast
Regulatory 2023-02-28 | Change in number of shares and votes in Ascelia Pharma AB PDF Report Presentation Webcast
